DUBLIN, Oct. 18,
2022 /PRNewswire/ -- Medtronic plc, the global
leader in medical technology, is introducing a new program called
My Insights exclusively made for individuals using the MiniMed™
770G system. Using an individual's data, My Insights relies on the
power of data science to provide personalized tips, trends, and
reminders that customers can use to help with their diabetes
management goals. The My Insights personalized recommendations are
shared via a monthly email with educational content that is most
relevant based on what an individual may currently be
experiencing.
This is the first program in diabetes management that goes
beyond generalized tips and instead shares personalized suggestions
using data from an integrated pump system.
The launch of this program adds to a list of first-of-its-kind
innovations and programs that Medtronic has brought to its patients
to augment their diabetes management. This includes the first
system to integrate insulin pumps and continuous glucose monitors
(CGM), the first technology to suspend insulin delivery and reduce
severe lows, the first Smart Insulin Pen, the first system to
automatically adjust background insulin, the first stand-alone CGM
with predictive alerts, and the first extended infusion set for up
to seven days of wear.
"With diabetes, I have a lot to keep track of to stay healthy.
My Insights provides me with personalized tips on how to improve
the experience of my MiniMed 770G pump system," said Melanie Licnerski who has been using Medtronic
technology for over two decades. "I did not expect the emotion I
got from the encouragement that My Insights provides. I didn't
realize that was something I was missing and really
appreciated."
By proactively identifying challenges and helping to celebrate
successes, My Insights adds to the experience MiniMed 770G system
provides to customers. The MiniMed 770G pump system, which is
available to people living with diabetes who are ages two and
above, uses self-adjusting technology to help prevent highs and
lows in blood glucose levels by automatically adjusting insulin
delivery every 5 minutes to adapt to an individual's unique needs.*
It also uses smart phone connectivity to view, share, and
automatically upload insulin and CGM data, and provides access to
future innovations via software upgrades.
"Our goal is to make life easier for individuals living with
diabetes," said Que Dallara, executive vice president &
president, Medtronic Diabetes. "As we continue our journey towards
a fully automated insulin delivery system, we want to surround our
customers with holistic support and empower them with tools to help
them achieve their goals. Diabetes is deeply personal and unique
for every individual, and we're pleased to offer this level of
personalization."
My Insights is available in the U.S. to those who use the
MiniMed 770G system. Users can opt-in to receive My Insights emails
at Diabetes.shop.
*Refers to SmartGuard™ Auto Mode. Some user interaction
required. Individual results may vary.
About the Diabetes Business at Medtronic
(www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Bold thinking. Bolder actions. We are
Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global
healthcare technology company that boldly attacks the most
challenging health problems facing humanity by searching out and
finding solutions. Our Mission — to alleviate pain, restore health,
and extend life — unites a global team of 90,000+ passionate people
across 150 countries. Our technologies and therapies treat 70
health conditions and include cardiac devices, surgical robotics,
insulin pumps, surgical tools, patient monitoring systems, and
more. Powered by our diverse knowledge, insatiable curiosity, and
desire to help all those who need it, we deliver innovative
technologies that transform the lives of two people every second,
every hour, every day. Expect more from us as we empower
insight-driven care, experiences that put people first, and better
outcomes for our world. In everything we do, we are engineering the
extraordinary. For more information on Medtronic (NYSE:MDT), visit
www.Medtronic.com and follow @Medtronic on Twitter and
LinkedIn.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
Contacts:
|
|
|
|
Janet Cho
|
Ryan
Weispfenning
|
Global
Communications
|
Investor
Relations
|
+1-818-403-2078
|
+1-763-505-4626
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medtronic-leverages-data-science-to-launch-first-of-its-kind-personalized-insights-program-for-people-living-with-diabetes-301651436.html
SOURCE Medtronic plc